Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nicotinamide riboside - Niagen Bioscience

Next Previous
Drug Profile

Nicotinamide riboside - Niagen Bioscience

Alternative Names: NIAGEN; nicotinamide riboside chloride; Nicotinamide-beta-riboside; Nicotinamide-ribonucleoside; Nicotinamide-ribose; NRC; SRT-647

Latest Information Update: 09 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University; Dartmouth College; Washington University
  • Developer Ecole Polytechnique Federale de Lausanne.; Emory University; National Institutes of Health (USA); Niagen Bioscience; University of Cambridge; University of Iowa; Washington University
  • Class Amides; Analgesics; Antivirals; Nicotinic acids; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ataxia telangiectasia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ataxia telangiectasia
  • Discontinued Alzheimer's disease; Cockayne syndrome; COVID 2019 infections; Heart failure; Mitochondrial myopathies; Pain; Retinal disorders

Most Recent Events

  • 20 Mar 2025 Niagen Bioscience has patent protection for nicotinamide riboside (NR) salt forms and derivatives in USA .
  • 19 Mar 2025 ChromaDex is now called Niagen Bioscience
  • 10 Feb 2025 ScandiBio Therapeutics terminates a phase-III clinical trials in COVID-2019 infections (Combination therapy) in Turkey (PO) as planned enrollment was not fulfilled (NCT04573153)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top